Year Founded
2018
Ownership
Private
Stage
Commercial
Modalities
Small moleculeSmall moleculeSynthetic peptide

HaiHe Biopharma General Information

Lead product Gumarontinib (MET inhibitor) approved in China and Japan. Paclitaxel oral solution approved in China for gastric cancer. Multiple compounds in clinical development including EZH1/2 inhibitor HH2853.

Contact Information

Website
Primary Industry
[ "Biotech", "Pharma" ]
Corporate Office
Shanghai, Pudong
China

Drug Pipeline

gumarontinib
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to HaiHe Biopharma's pipeline data

Book a demo

Key Partnerships

Taiho Pharmaceutical, Shanghai Institute of Materia Medica, Tigermed, Junshi Biosciences, 3D Medicines, Jiuzhou Pharmaceutical

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

HaiHe Biopharma Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view HaiHe Biopharma's complete valuation and funding history, request access »

HaiHe Biopharma Investors

Huagai Capital
Investor Type: Venture Capital
Holding: Minority
Yingke PE
Investor Type: Venture Capital
Holding: Minority
CSPC
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 9 investors. Get the full list »